Zobrazeno 1 - 10
of 49
pro vyhledávání: '"O Giles, Best"'
Autor:
Larissa Belov, Kieran J. Matic, Susannah Hallal, O. Giles Best, Stephen P. Mulligan, Richard I. Christopherson
Publikováno v:
Journal of Extracellular Vesicles, Vol 5, Iss 0, Pp 1-12 (2016)
Extracellular vesicles (EV) are membranous particles (30–1,000 nm in diameter) secreted by cells. Important biological functions have been attributed to 2 subsets of EV, the exosomes (bud from endosomal membranes) and the microvesicles (MV; bud fro
Externí odkaz:
https://doaj.org/article/e11e1da5dbbb4967b533a00eedf68edc
Publikováno v:
Haematologica, Vol 103, Iss 7 (2018)
Externí odkaz:
https://doaj.org/article/c53d8c739d954f62a9844a8bff271e8e
Autor:
Bryone J. Kuss, Anya K. Hotinski, Karen M. Lower, Cuc Do, Lauren A. Thurgood, O. Giles Best, Stephen P. Mulligan, Sinoula Apostolou
Publikováno v:
British Journal of Haematology. 193:556-560
The clinical significance of low-frequency deletions of 17p13 [tumour protein p53 (TP53)] in patients with chronic lymphocytic leukaemia (CLL) is currently unclear. Low-frequency del17p clones (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2c0991d3a6ae1da87845c582140816d
https://doi.org/10.1111/bjh.17394
https://doi.org/10.1111/bjh.17394
Autor:
Narjis Fatima, Yandong Shen, Kyle Crassini, Edwin J. Iwanowicz, Henk Lang, Donald S. Karanewsky, Richard I Christopherson, Stephen P Mulligan, O. Giles Best
Despite advances in treatment, a significant proportion of patients with chronic lymphocytic leukaemia (CLL) will relapse with drug-resistant disease.Recent studies demonstrate that the imipridones ONC-201 and ONC-212 and the more potent TR-compounds
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f13f551dcc5277809bd4feabf23a7cca
https://doi.org/10.1101/2022.03.07.483345
https://doi.org/10.1101/2022.03.07.483345
Autor:
Juhura G. Almazi, Munther Alomari, Larissa Belov, O. Giles Best, Yandong Shen, Mark E. Graham, Stephen P. Mulligan, Richard I. Christopherson
Publikováno v:
Nucleosides, nucleotidesnucleic acids. 41(3)
Triple combination FCR (fludarabine, cyclophosphamide and rituximab) is often used as front-line treatment for chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. Results from our laboratory indicate that 2-FaraAMP (fludarabine) has multip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c8f03cfd1626e6855197bf152900462
https://pubmed.ncbi.nlm.nih.gov/34886743
https://pubmed.ncbi.nlm.nih.gov/34886743
Publikováno v:
British Journal of Haematology. 186:668-684
Chronic lymphocytic leukaemia (CLL) is characterised by the clonal expansion of mature, CD5 positive, B lymphocytes in the blood, marrow, lymph nodes and spleen. For the majority of patients, CLL follows an indolent clinical course, while a proportio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09a81439275081554d1221b8e7ea8028
https://doi.org/10.1111/bjh.16102
https://doi.org/10.1111/bjh.16102
Autor:
Suneet Sandhu, O. Giles Best, Stephen P. Mulligan, Narjis Fatima, Richard I. Christopherson, Kyle Crassini, Yandong Shen
Publikováno v:
Leukemia & Lymphoma. 60:1632-1643
Several key pathways mediate signaling via the B-cell receptor, including the mitogen-activated protein kinase-ERK1/2 pathway. However, inhibition of MEK1/2, a key component of the MAPK-ERK1/2 signaling cascade, results in paradoxical activation of A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7ace7fbefaf9b177fc9c914a1d28bf9
https://doi.org/10.1080/10428194.2018.1542148
https://doi.org/10.1080/10428194.2018.1542148
Autor:
O. Giles Best, Narjis Fatima, Michael O'Dwyer, Michael O'Neill, Yandong Shen, Stephen P. Mulligan, Richard I. Christopherson, Kyle Crassini
Publikováno v:
Blood Adv
The B-cell receptor signaling pathway and dysregulation of the Bcl-2 family of proteins play crucial roles in the pathogenesis of chronic lymphocytic leukemia (CLL). Despite significant advances in the treatment of the disease, relapse and drug resis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bdd7136a8077683d888cbbde325b33f
https://europepmc.org/articles/PMC7594376/
https://europepmc.org/articles/PMC7594376/
Autor:
Kyle Crassini, Yandong Shen, O. Giles Best, Michael O'Neill, Richard I. Christopherson, Stephen P. Mulligan, Michael O'Dwyer
Publikováno v:
British journal of haematology. 182(5)
Despite significant advances in treatment, chronic lymphocytic leukaemia (CLL) remains an incurable disease. Ibrutinib and idelalisib, which inhibit Bruton Tyrosine kinase (BTK) and phosphoinositol-3 (PI3) kinase-δ respectively, have become importan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::032dff8f2e9ff07642cd239c7e4a6c68
https://pubmed.ncbi.nlm.nih.gov/29978459
https://pubmed.ncbi.nlm.nih.gov/29978459
Autor:
Kyle Crassini, William Stevenson, Yandong Shen, O. Giles Best, Chris Ward, Stephen P. Mulligan, Richard I. Christopherson
Publikováno v:
British journal of haematology. 182(3)
The survival and proliferation of chronic lymphocytic leukaemia (CLL) cells is driven by multiple signalling pathways, including those mediated by the B cell, Toll-like and chemokine receptors. Many of these pathways converge on the same signalling m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad87bbc8d4f3dd4237f657ca2ec351d4
https://pubmed.ncbi.nlm.nih.gov/29767410
https://pubmed.ncbi.nlm.nih.gov/29767410